Chemotherapy and antiangiogenics in biliary tract cancer
Mené sur 124 patients atteints d'un cancer avancé des voies biliaires, cet essai randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de cédiranib à une chimiothérapie combinant cisplatine et gemcitabine
In the landmark phase 3 ABC-02 trial, Valle and colleagues established the combination of gemcitabine and cisplatin as the standard of care for first-line treatment of patients with advanced biliary tract cancer. This regimen showed a median overall survival of nearly 1 year, and based on this encouraging result, the combination of gemcitabine and platinum has emerged as the chemotherapy backbone for testing the addition of targeted treatments. Unfortunately, trials combining an anti-VEGF agent or an anti-EGFR agent with gemcitabine and platinum have yielded disappointing results, but similar efforts with agents targeting alternative pathways are underway.
The Lancet Oncology , commentaire en libre accès, 2014